DOCSLIB.ORG

Disease Control Newsletter Is Available on the MDH IDCN Web Site: (

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ISEASE ONTROL EWSLETTER DVolume 46, Number 1 (pages 1-30) C N 2019 Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2018 Introduction Anaplasmosis Assessment of the population’s health is a core public health function. Anaplasmosis, caused by Anaplasma Surveillance for communicable diseases is one type of assessment. Epidemiologic phagocytophilum, is transmitted surveillance is the systematic collection, analysis, and dissemination of health by bites from Ixodes scapularis, data for the planning, implementation, and evaluation of health programs. the blacklegged tick. Although the The Minnesota Department of Health (MDH) collects information on infectious organism that causes anaplasmosis diseases for the purposes of determining disease impact, assessing trends in was previously known by other disease occurrence, characterizing affected populations, prioritizing control names and thought to be a part of efforts, and evaluating prevention strategies. Prompt reporting allows outbreaks the genus Ehrlichia, anaplasmosis and to be recognized in a timely fashion when control measures are most likely to be ehrlichiosis (due to E. chaffeensis) are effective in preventing additional cases. distinct diseases caused by different rickettsial species. The same tick vector In Minnesota, communicable disease reporting is centralized, whereby reporting also transmits the etiologic agents of sources submit standardized reports to MDH. Cases of disease are reported Lyme disease, babesiosis, ehrlichiosis pursuant to Minnesota Rules Governing Communicable Diseases (Minnesota (due to E. muris), and Powassan Rules 4605.7000 -4605.7800). The diseases listed in Table 1 must be reported virus. In rare circumstances, A. to MDH. As stated in the rules, physicians, health care facilities, laboratories, phagocytophilum may be transmitted veterinarians, and others are required to report these diseases. Reporting by blood transfusion. sources may designate an individual within an institution to perform routine reporting duties (e.g., an infection preventionist for a hospital). Data maintained In 2018, 496 confirmed or probable by MDH are private and protected under the Minnesota Government Data cases (8.9 cases per 100,000 Practices Act (Section 13.3805). population) were reported, down from the 638 cases reported in 2017 (Figure Since April 1995, MDH has participated as an Emerging Infections Program 1). Despite some annual fluctuations in (EIP) site funded by the U.S. Centers for Disease Control and Prevention (CDC) reported cases, the overall trend is an and, through this program, has implemented active hospital- and laboratory- increase in yearly case totals over time, based surveillance for several conditions, including selected bacterial diseases, with a median of 627 cases reported foodborne diseases, tickborne diseases, and hospitalized influenza cases. per year since 2010. Sixty-two percent (307) of cases reported were male. Isolates of pathogens from certain diseases are required to be submitted to The median age of cases was 61 years MDH (Table 1: Minnesota Rules Governing Communicable Diseases (Minnesota (range, 2 to 92), 17 years older than Rules 4605.7000-4605.7800). The MDH Public Health Laboratory (PHL) performs the median age of confirmed Lyme microbiologic and molecular evaluation of isolates, such as pulsed-field gel disease cases. As is typical, most cases electrophoresis (PFGE) and whole genome sequencing (WGS), to determine had illness onsets during the summer whether isolates (e.g., enteric pathogens such as Salmonella and Escherichia coli months, with 72% of cases reporting O157:H7, and invasive pathogens such as Group A streptococcus) are related and illness onsets in June and July. In 2018, potentially associated with a common source. Testing of submitted isolates also 132 (27%) cases were hospitalized for allows detection and monitoring of antimicrobial resistance. their infection, with a median duration of 4 days (range, 2 to 33 days). Table 2 summarizes cases of selected communicable diseases reported during 2018 by district of the patient’s residence. Pertinent observations for some continued on page 4 of these diseases are presented below. Incidence rates in this report were calculated using disease-specific numerator data collected by MDH and a standardized set of denominator data derived from U.S. Census data. Disease INSIDE: incidence is categorized as occurring within the seven-county Twin Cities metropolitan area (metropolitan area) or outside of it in Greater Minnesota Emerging Infections in Clinical Practice and (unless otherwise indicated). Public Health Announcement and Registration ...............................................28 Table 1. Diseases Reportable to the Minnesota Department of Health Reportable Diseases, MN Rules 4605.7000 to 4605.7900 Diseases Reportable to the Minnesota Department of Health 651-201-5414 or 1-877-676-5414 24 hours a day, 7 days a week REPORT IMMEDIATELY BY TELEPHONE Anthrax (Bacillus anthracis) M Hemolytic uremic syndrome M Rabies (animal and human cases and suspected Botulism (Clostridium botulinum) Measles (rubeola) M cases) Brucellosis (Brucella spp.) M Melioidosis (Burkholderia pseudomallei) M * Rubella and congenital rubella syndrome M Cholera (Vibrio cholerae) M Meningococcal disease (Neisseria meningitidis) Severe Acute Respiratory Syndrome (SARS) M R Diphtheria (Corynebacterium diphtheriae) M (invasive) M S Smallpox (variola) M Free-living amebic infection M Middle East Respiratory Syndrome (MERS) M Tularemia (Francisella tularensis) M (including at least: Acanthamoeba spp., Orthopox virus M Unusual or increased case incidence of any Naegleria fowleri, Balamuthia spp., Sappinia Plague (Yersinia pestis) M suspect infectious illness M spp.) Poliomyelitis M Viral hemorrhagic fever M Glanders (Burkholderia mallei) M * Coxiella burnetii (including but not limited to Ebola virus disease Q fever ( ) M and Lassa fever) REPORT WITHIN ONE WORKING DAY Amebiasis (Entamoeba histolytica/dispar) Haemophilus influenzae disease (all invasive Staphylococcus aureus M Anaplasmosis (Anaplasma phagocytophilum) disease) M S (only vancomycin-intermediate Staphylococcus Hantavirus infection aureus [VISA], vancomycin-resistant Arboviral disease Staphylococcus aureus [VRSA], and death or (including, but not limited to, La Crosse Hepatitis (all primary viral types including A, B, critical illness due to community-associated encephalitis, eastern equine encephalitis, C, D, and E) B Staphylococcus aureus in a previously healthy western equine encephalitis, St. Louis Histoplasmosis (Histoplasma capsulatum) encephalitis, West Nile virus disease, Powassan individual) virus disease, and Jamestown Canyon virus Human immunodeficiency virus (HIV) infection, Streptococcal disease - invasive disease caused disease) including Acquired Immunodeficiency by Groups A and B streptococci and Syndrome (AIDS) B S. pneumoniae M S Babesiosis (Babesia spp.) Influenza M Blastomyces dermatitidis Streptococcal disease - non-invasive Blastomycosis ( ) (unusual case incidence, critical illness, or S. pneumoniae Candida auris M ** laboratory-confirmed cases) (urine antigen laboratory-confirmed Campylobacteriosis (Campylobacter spp.) M Kawasaki disease pneumonia) Carbapenem-resistant Enterobacteriaceae (CRE) M Kingella spp. (invasive only) M S Syphilis (Treponema pallidum) B Cat scratch disease (infection caused by Legionellosis (Legionella spp.) M Tetanus (Clostridium tetani) Bartonella species) Leprosy (Hansen’s disease) (Mycobacterium Toxic shock syndrome M Chancroid (Haemophilus ducreyi) leprae) Toxoplasmosis (Toxoplasma gondii) Chikungunya virus disease Leptospirosis (Leptospira interrogans) Transmissible spongiform encephalopathy Chlamydia trachomatis infections Listeriosis (Listeria monocytogenes) M Trichinosis (Trichinella spiralis) Coccidioidomycosis Lyme disease (Borrelia burgdorferi, and other Tuberculosis (Mycobacterium tuberculosis Cronobacter sakazakii in infants under one year Borrelia spp.) complex) M of age M Malaria (Plasmodium spp.) (pulmonary or extrapulmonary sites of disease, Cryptosporidiosis (Cryptosporidium spp.) M Meningitis (caused by viral agents) including clinically diagnosed disease). Latent Cyclosporiasis (Cyclospora spp.) M Mumps M tuberculosis infection is not reportable. Dengue virus infection Neonatal sepsis M S Typhus (Rickettsia spp.) Diphyllobothrium latum infection (bacteria isolated from a sterile site, Unexplained deaths and unexplained critical Ehrlichia excluding coagulase-negative Staphylococcus) illness Ehrlichiosis ( spp.) less than seven days after birth (possibly due to infectious cause) M Encephalitis (caused by viral agents) Pertussis (Bordetella pertussis) M Varicella (chickenpox) M Enteric Escherichia coli infection M Vibrio spp. M (E. coli O157:H7, other Shiga toxin-producing Psittacosis (Chlamydophila psittaci) E. coli, enterohemorrhagic Retrovirus infections Yellow fever E. coli, enteropathogenic E. coli, enteroinvasive Salmonellosis, including typhoid (Salmonella Yersiniosis (enteric Yersinia spp. regardless of E. coli, enteroaggregative spp.) M specimen source) M E. coli, enterotoxigenic E. coli, or other Shigellosis (Shigella spp.) M Zika virus disease B pathogenic E. coli) Spotted fever rickettsiosis Zoster (shingles) M Giardiasis (Giardia intestinalis) (Rickettsia spp. infections, including Rocky (all cases <18 years old; unusual case incidence/ Gonorrhea (Neisseria gonorrhoeae infections) Mountain spotted fever) complications
Recommended publications
  • Official Nh Dhhs Health Alert

    Official Nh Dhhs Health Alert

    THIS IS AN OFFICIAL NH DHHS HEALTH ALERT Distributed by the NH Health Alert Network [email protected] May 18, 2018, 1300 EDT (1:00 PM EDT) NH-HAN 20180518 Tickborne Diseases in New Hampshire Key Points and Recommendations: 1. Blacklegged ticks transmit at least five different infections in New Hampshire (NH): Lyme disease, Anaplasma, Babesia, Powassan virus, and Borrelia miyamotoi. 2. NH has one of the highest rates of Lyme disease in the nation, and 50-60% of blacklegged ticks sampled from across NH have been found to be infected with Borrelia burgdorferi, the bacterium that causes Lyme disease. 3. NH has experienced a significant increase in human cases of anaplasmosis, with cases more than doubling from 2016 to 2017. The reason for the increase is unknown at this time. 4. The number of new cases of babesiosis also increased in 2017; because Babesia can be transmitted through blood transfusions in addition to tick bites, providers should ask patients with suspected babesiosis whether they have donated blood or received a blood transfusion. 5. Powassan is a newer tickborne disease which has been identified in three NH residents during past seasons in 2013, 2016 and 2017. While uncommon, Powassan can cause a debilitating neurological illness, so providers should maintain an index of suspicion for patients presenting with an unexplained meningoencephalitis. 6. Borrelia miyamotoi infection usually presents with a nonspecific febrile illness similar to other tickborne diseases like anaplasmosis, and has recently been identified in one NH resident. Tests for Lyme disease do not reliably detect Borrelia miyamotoi, so providers should consider specific testing for Borrelia miyamotoi (see Attachment 1) and other pathogens if testing for Lyme disease is negative but a tickborne disease is still suspected.
  • 2012 Case Definitions Infectious Disease

    2012 Case Definitions Infectious Disease

    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
  • Avoidance of Mechanisms of Innate Immune Response by Neisseria Gonorrhoeae

    Avoidance of Mechanisms of Innate Immune Response by Neisseria Gonorrhoeae

    ADVANCEMENTS OF MICROBIOLOGY – POSTĘPY MIKROBIOLOGII 2019, 58, 4, 367–373 DOI: 10.21307/PM–2019.58.4.367 AVOIDANCE OF MECHANISMS OF INNATE IMMUNE RESPONSE BY NEISSERIA GONORRHOEAE Jagoda Płaczkiewicz* Department of Virology, Institute of Microbiology, Faculty of Biology, University of Warsaw Submitted in July, accepted in October 2019 Abstract: Neisseria gonorrhoeae (gonococcus) is a Gram-negative bacteria and an etiological agent of the sexually transmitted disease – gonorrhea. N. gonorrhoeae possesses many mechanism to evade the innate immune response of the human host. Most are related to serum resistance and avoidance of complement killing. However the clinical symptoms of gonorrhea are correlated with a significant pres- ence of neutrophils, whose response is also insufficient and modulated by gonococci. 1. Introduction. 2. Adherence ability. 3. Serum resistance and complement system. 4. Neutrophils. 4.1. Phagocytosis. 4.1.1. Oxygen- dependent intracellular killing. 4.1.2. Oxygen-independent intracellular killing. 4.2. Neutrophil extracellular traps. 4.3. Degranulation. 4.4. Apoptosis. 5. Summary UNIKANIE MECHANIZMÓW WRODZONEJ ODPOWIEDZI IMMUNOLOGICZNEJ PRZEZ NEISSERIA GONORRHOEAE Streszczenie: Neisseria gonorrhoeae (gonokok) to Gram-ujemna dwoinka będąca czynnikiem etiologicznym choroby przenoszonej drogą płciową – rzeżączki. N. gonorrhoeae posiada liczne mechanizmy umożliwiające jej unikanie wrodzonej odpowiedzi immunologicznej gospodarza. Większość z nich związana jest ze zdolnością gonokoków do manipulowania układem dopełniacza gospodarza oraz odpor- nością tej bakterii na surowicę. Jednakże symptomy infekcji N. gonorrhoeae wynikają między innymi z obecności licznych neutrofili, których aktywność jest modulowana przez gonokoki. 1. Wprowadzenie. 2. Zdolność adherencji. 3. Surowica i układ dopełniacza. 4. Neutrofile. 4.1. Fagocytoza. 4.1.1. Wewnątrzkomórkowe zabijanie zależne od tlenu. 4.1.2.
  • 3- Chlamydia, Syphilis & Gonorrhea (STD)

    3- Chlamydia, Syphilis & Gonorrhea (STD)

    3- Chlamydia, syphilis & gonorrhea (STD) Microbiology 435’s Teamwork Reproductive Block Learning Objectives: ● Know the causative agents of syphilis, gonorrhea and Chlamydia infections. ● Realize that these three infections are acquired through sexual intercourse. ● Know the pathogenesis of syphilis, gonorrhea and Chlamydia infection. ● Describe the clinical feature of the primary, secondary tertiary syphilis and complications. ● Recall the different diagnostic methods for the different stages of syphilis. ● Describe the clinical features of gonorrhea that affect only men, only women and those ones which affect both sexes. ● Describe the different laboratory tests for the diagnosis of gonorrhea ● Describe the morphology and the distinct life cycle of the Chlamydia. ● Realize what are the different genera, species and serotypes of the family Chlamydophila. ● Recognize that Chlamydia cause different diseases that affect the eye (causing trachoma) and the respiratory system (mainly cause a typical pneumonia). ● Know the different urogenital clinical syndromes caused by Chlamydia trachomatis that affect men, women and both sex. ● Realize that these urogenital syndromes are difficult to differentiate clinically from the similar ones caused by N.gonorrheae. ● Know the treatment of syphilis, gonorrhea and Chlamydia infections. ● Realize that there are no effective vaccines against all these three diseases. Important Resources: 435 females & males slides and ​ ​ ​ Males notes notes, wikipedia, ​ ​ Females notes Lippincott’s Illustrated Reviews: Microbiology- ​ ​ Extra Third Edition ​ ​ Editing file: Here ​ ​ Credit: Team members ​ Introduction (take-home message) ● Syphilis, Chlamydia and Gonorrhea are main STDs, caused by delicate organisms that cannot survive ​ ​ ​ outside the body. Infection may not be localized. ​ ​ ● Clinical presentation may be similar (urethral or genital discharge, ulcers). ● One or more organisms (Bacteria, virus, parasite) may be transmitted by sexual contact.
  • Molecular Characterization of the Burkholderia Cenocepacia Dcw Operon and Ftsz Interactors As New Targets for Novel Antimicrobial Design

    Molecular Characterization of the Burkholderia Cenocepacia Dcw Operon and Ftsz Interactors As New Targets for Novel Antimicrobial Design

    antibiotics Article Molecular Characterization of the Burkholderia cenocepacia dcw Operon and FtsZ Interactors as New Targets for Novel Antimicrobial Design Gabriele Trespidi y , Viola Camilla Scoffone y, Giulia Barbieri , Giovanna Riccardi, Edda De Rossi * and Silvia Buroni * Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, 27100 Pavia, Italy; [email protected] (G.T.); viola.scoff[email protected] (V.C.S.); [email protected] (G.B.); [email protected] (G.R.) * Correspondence: [email protected] (E.D.R.); [email protected] (S.B.) These authors contributed equally to this work. y Received: 20 October 2020; Accepted: 23 November 2020; Published: 24 November 2020 Abstract: The worldwide spread of antimicrobial resistance highlights the need of new druggable cellular targets. The increasing knowledge of bacterial cell division suggested the potentiality of this pathway as a pool of alternative drug targets, mainly based on the essentiality of these proteins, as well as on the divergence from their eukaryotic counterparts. People suffering from cystic fibrosis are particularly challenged by the lack of antibiotic alternatives. Among the opportunistic pathogens that colonize the lungs of these patients, Burkholderia cenocepacia is a well-known multi-drug resistant bacterium, particularly difficult to treat. Here we describe the organization of its division cell wall (dcw) cluster: we found that 15 genes of the dcw operon can be transcribed as a polycistronic mRNA from mraZ to ftsZ and that its transcription is under the control of a strong promoter regulated by MraZ. B. cenocepacia J2315 FtsZ was also shown to interact with the other components of the divisome machinery, with a few differences respect to other bacteria, such as the direct interaction with FtsQ.
  • AMD Projects: Deadly Disease Databases

    AMD Projects: Deadly Disease Databases

    CDC’s AMD Program AMD Projects Innovate • Transform • Protect CDC’s Advanced Molecular Detection (AMD) program fosters scientific innovation in genomic sequencing, epidemiology, and bioinformatics to transform public health and protect people from disease threats. AMD Project: Deadly Disease Databases Whole genome analysis and database development for anthrax (Bacillus anthracis), melioidosis (Burkholderia pseudomallei), and Brucellosis (Brucella spp.) Epidemiologists and forensic professionals can use whole genome sequencing – a way of determining an organism’s complete, detailed genome – and large databases to determine the source of dangerous germs. Having a large, accessible collection of disease pathogens could help scientists quickly find out if a certain illness is naturally occurring or the result of bioterrorism. CDC is establishing a public database where scientists from around the world can share information about these potentially deadly CDC is establishing public databases so that diseases. CDC scientists have begun sequencing the organisms that scientists from around the world can share information about deadly diseases like cause anthrax (Bacillus anthracis), brucellosis (Brucella spp.), and anthrax, brucellosis, and melioidosis. melioidosis (Burkholderia pseudomallei), three pathogens that could occur naturally or as the result of bioterrorism. Current methods of determining the genetic structure of these organisms are not standardized and sometimes not effective. Using whole genome sequencing for these pathogens will allow scientists www.cdc.gov/amd Updated: May 2017 to accurately and quickly find the geographic origin of the isolates and will improve overall knowledge and understanding of them. Having a detailed database of these genomes will also ensure quicker and more effective responses to outbreaks. For more information on anthrax, please visit www.cdc.gov/anthrax/index.html.
  • Drug-Resistant Neisseria Gonorrhoeae Threat Level Urgent

    Drug-Resistant Neisseria Gonorrhoeae Threat Level Urgent

    DRUG-RESISTANT NEISSERIA GONORRHOEAE THREAT LEVEL URGENT 550,000 1.14M $133.4M Estimated Total new Annual discounted drug-resistant infections lifetime direct infections each each year medical costs year Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted disease (STD) that can result in life-threatening ectopic pregnancy and infertility, and can increase the risk of getting and giving HIV. WHAT YOU NEED TO KNOW EMERGING ANTIBIOTIC RESISTANCE ■ Gonorrhea has quickly developed resistance to all Gonorrhea rapidly develops resistance to antibiotics—ceftriaxone but one class of antibiotics, and half of all infections is the last recommended treatment. are resistant to at least one antibiotic. Tests to detect 35% 1980s: 2007: 2012: resistance are not available at time of treatment. Penicillin Ciprofloxacin Cefixime and tetracycline no longer no longer 30% no longer recommended recommended ■ Gonorrhea spreads easily. Some men and most women recommended as a first-line regimen do not have symptoms and may not know they are 25% infected, increasing spread. 20% ■ Untreated gonorrhea can cause serious and permanent health problems in women and men, including ectopic 15% pregnancy and infertility, and can spread to the blood resulting in cardiovascular and neurological problems. 10% Resistance or Emerging Resistance or Emerging Resistance Percent of Gonococcal Infections with Infections of Gonococcal Percent 5% 0% 2000 2002 2004 2006 2008 2010 2012 2014 2016 Azithromycin Ciprofloxacin Cefixime Penicillin Ceftriaxone Tetracycline STD Clinic
  • Gonorrhea, Chlamydia, and Syphilis

    Gonorrhea, Chlamydia, and Syphilis

    2019 GONORRHEA, CHLAMYDIA, AND SYPHILIS AND CHLAMYDIA, GONORRHEA, Dedication TAG would like to thank the National Coalition of STD Directors for funding and input on the report. THE PIPELINE REPORT Pipeline for Gonorrhea, Chlamydia, and Syphilis By Jeremiah Johnson Introduction The current toolbox for addressing gonorrhea, chlamydia, and syphilis is inadequate. At a time where all three epidemics are dramatically expanding in locations all around the globe, including record-breaking rates of new infections in the United States, stakeholders must make do with old tools, inadequate systems for addressing sexual health, and a sparse research pipeline of new treatment, prevention, and diagnostic options. Lack of investment in sexual health research has left the field with inadequate prevention options, and limited access to infrastructure for testing and treatment have allowed sexually transmitted infections (STIs) to flourish. The consequences of this underinvestment are large: according to the World Health Organization (WHO), in 2012 there were an estimated 357 million new infections (roughly 1 million per day) of the four curable STIs: gonorrhea, chlamydia, syphilis, and trichomoniasis.1 In the United States, the three reportable STIs that are the focus of this report—gonorrhea, chlamydia, and syphilis—are growing at record paces. In 2017, a total of 30,644 cases of primary and secondary (P&S) syphilis—the most infectious stages of the disease—were reported in the United States. Since reaching a historic low in 2000 and 2001, the rate of P&S syphilis has increased almost every year, increasing 10.5% during 2016–2017. Also in 2017, 555,608 cases of gonorrhea were reported to the U.S.
  • Insights Into the Pathogenicity of Burkholderia Pseudomallei

    Insights Into the Pathogenicity of Burkholderia Pseudomallei

    REVIEWS Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei W. Joost Wiersinga*, Tom van der Poll*, Nicholas J. White‡§, Nicholas P. Day‡§ and Sharon J. Peacock‡§ Abstract | Burkholderia pseudomallei is a potential bioterror agent and the causative agent of melioidosis, a severe disease that is endemic in areas of Southeast Asia and Northern Australia. Infection is often associated with bacterial dissemination to distant sites, and there are many possible disease manifestations, with melioidosis septic shock being the most severe. Eradication of the organism following infection is difficult, with a slow fever-clearance time, the need for prolonged antibiotic therapy and a high rate of relapse if therapy is not completed. Mortality from melioidosis septic shock remains high despite appropriate antimicrobial therapy. Prevention of disease and a reduction in mortality and the rate of relapse are priority areas for future research efforts. Studying how the disease is acquired and the host–pathogen interactions involved will underpin these efforts; this review presents an overview of current knowledge in these areas, highlighting key topics for evaluation. Melioidosis is a serious disease caused by the aerobic, rifamycins, colistin and aminoglycosides), but is usually Gram-negative soil-dwelling bacillus Burkholderia pseu- susceptible to amoxicillin-clavulanate, chloramphenicol, domallei and is most common in Southeast Asia and doxycycline, trimethoprim-sulphamethoxazole, ureido- Northern Australia. Melioidosis is responsible for 20% of penicillins, ceftazidime and carbapenems2,4. Treatment all community-acquired septicaemias and 40% of sepsis- is required for 20 weeks and is divided into intravenous related mortality in northeast Thailand. Reported cases are and oral phases2,4. Initial intravenous therapy is given likely to represent ‘the tip of the iceberg’1,2, as confirmation for 10–14 days; ceftazidime or a carbapenem are the of disease depends on bacterial isolation, a technique that drugs of choice.
  • Antigen Detection Assay for the Diagnosis of Melioidosis

    Antigen Detection Assay for the Diagnosis of Melioidosis

    PI: Title: Antigen Detection assay for the Diagnosis of Melioidosis Received: 12/05/2013 FOA: PA10-124 Council: 05/2014 Competition ID: ADOBE-FORMS-B1 FOA Title: NIAID ADVANCED TECHNOLOGY STTR (NIAID-AT-STTR [R41/R42]) 2 R42 AI102482-03 Dual: Accession Number: 3650491 IPF: 3966401 Organization: INBIOS INTERNATIONAL, INC. Former Number: Department: IRG/SRG: ZRG1 IDM-V (12)B AIDS: N Expedited: N Subtotal Direct Costs Animals: N New Investigator: N (excludes consortium F&A) Humans: Y Early Stage Investigator: N Year 3: Clinical Trial: N Year 4: Current HS Code: E4 Year 5: HESC: N Senior/Key Personnel: Organization: Role Category: Always follow your funding opportunity's instructions for application format. Although this application demonstrates good grantsmanship, time has passed since the grantee applied. The sample may not reflect the latest format or rules. NIAID posts new samples periodically: https://www.niaid.nih.gov/grants-contracts/sample-applications The text of the application is copyrighted. You may use it only for nonprofit educational purposes provided the document remains unchanged and the PI, the grantee organization, and NIAID are credited. Note on Section 508 conformance and accessibility: We have reformatted these samples to improve accessibility for people with disabilities and users of assistive technology. If you have trouble accessing the content, please contact the NIAID Office of Knowledge and Educational Resources at [email protected]. Additions for Review Accepted Publication Accepted manuscript news Post-submission supplemental material. Information about manuscript accepted for publication. OMB Number: 4040-0001 Expiration Date: 06/30/2011 APPLICATION FOR FEDERAL ASSISTANCE 3. DATE RECEIVED BY STATE State Application Identifier SF 424 (R&R) 1.
  • Monthly Reportable Diseases Summary

    Monthly Reportable Diseases Summary

    Monthly Reportable Diseases Summary June 2021 The data in the Monthly Disease Reports are provisional, based on current reports in the Michigan Disease Surveillance System (MDSS) made by local public health departments. The MDSS is a dynamic, continually active system; counts of disease are constantly changing as cases are investigated, confirmed as cases, or ruled out as not meeting the case definition. Each Monthly Disease Report reflects this constant activity as the numbers may slightly fluctuate each month. Therefore, it should be kept in mind that numbers in the Monthly Disease Reports are NOT final and should be used only to generally monitor Ottawa County trends over time. Unknown, suspect, probable and confirmed cases of the reportable condition are included in the report. An updated report is published each month. Specific data requests and questions should be directed to the following: Compiled by Derick N. Chia, MPH Epidemiologist [email protected] We value your feedback. Please use this QR code or click on the link below to tell us what you think of this report: Link to Survey 12251 James Street Holland, MI 49424-9661 www.miottawa.org/healthdata June 2021 Reportable conditions that are italicized have an accompanying graph at the end of the monthly section. Cases Reported in Last 4 Months** Year Total Through June Year End Disease Group Reportable Condition Mar-21 Apr-21 May-21 Jun-21 2018 2019 2020 2021 2020 Foodborne Amebiasis - 1 - - - - - 1 - Botulism - Foodborne - - - - - - - - - Campylobacter 2 4 1 6 33 29 16 22
  • Chlamydia, Gonorrhoea, Trichomoniasis and Syphilis

    Chlamydia, Gonorrhoea, Trichomoniasis and Syphilis

    Research Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016 Jane Rowley,a Stephen Vander Hoorn,b Eline Korenromp,c Nicola Low,d Magnus Unemo,e Laith J Abu- Raddad,f R Matthew Chico,g Alex Smolak,f Lori Newman,h Sami Gottlieb,a Soe Soe Thwin,a Nathalie Brouteta & Melanie M Taylora Objective To generate estimates of the global prevalence and incidence of urogenital infection with chlamydia, gonorrhoea, trichomoniasis and syphilis in women and men, aged 15–49 years, in 2016. Methods For chlamydia, gonorrhoea and trichomoniasis, we systematically searched for studies conducted between 2009 and 2016 reporting prevalence. We also consulted regional experts. To generate estimates, we used Bayesian meta-analysis. For syphilis, we aggregated the national estimates generated by using Spectrum-STI. Findings For chlamydia, gonorrhoea and/or trichomoniasis, 130 studies were eligible. For syphilis, the Spectrum-STI database contained 978 data points for the same period. The 2016 global prevalence estimates in women were: chlamydia 3.8% (95% uncertainty interval, UI: 3.3–4.5); gonorrhoea 0.9% (95% UI: 0.7–1.1); trichomoniasis 5.3% (95% UI:4.0–7.2); and syphilis 0.5% (95% UI: 0.4–0.6). In men prevalence estimates were: chlamydia 2.7% (95% UI: 1.9–3.7); gonorrhoea 0.7% (95% UI: 0.5–1.1); trichomoniasis 0.6% (95% UI: 0.4–0.9); and syphilis 0.5% (95% UI: 0.4–0.6). Total estimated incident cases were 376.4 million: 127.2 million (95% UI: 95.1–165.9 million) chlamydia cases; 86.9 million (95% UI: 58.6–123.4 million) gonorrhoea cases; 156.0 million (95% UI: 103.4–231.2 million) trichomoniasis cases; and 6.3 million (95% UI: 5.5–7.1 million) syphilis cases.